TABLE 6.

Available literature on ESD of T1b EC

	Current report	Van Munster et al (2021)25	Othman et al (2021)12	Namikawa et al (2021)33	Hsu et al (2021)34	Al-Kaabi et al (2021)35	Zhang et al (2019)36
Location	USA and Brazil	Netherlands	USA	Japan	Taiwan	Europe	China
Patient diagnosis	T1b EAC and ESCC	BE, T1a, T1b EAC	T1a and T1b EAC	T1a and T1b submucosa ESCC	High-grade dysplasia and T1a and T1b ESCC	T1a, T1b, T2 ESCC undergoing ESD after chemoradiation therapy	T1a, T1b ESCC
Study design	Multicenter retrospective	Multicenter retrospective study	Single-center retrospective study	Single-site retrospective	Single-site retrospective	Multicenter retrospective	Single-site retrospective cohort study
No. of T1b patients	66	67	17	10	40	8	82
Median size, mm [p25-p75]	25.0 [19.0–35.0].	N/A*	15* [13.5–20]	24.5* [3–70]	32.8 ± 16.9*,† (10–100)	N/A*	26* [20–36]
En-bloc resection rate, %	92.4	99	100	N/A*	N/A*	N/A*	N/A*
R0 resection rate, %	54.5	50	41.2	N/A*	N/A*	N/A*	N/A*
Overall survival	86.36% (20-mo follow-up)	N/A*	N/A*	N/A*	Calculated 10-y survival >85% for >sm1 with adjuvant therapy	N/A*	90.9% (21-mo follow-up)

EAC, Esophageal adenocarcinoma; BE, Barrett’s esophagus; ESCC, esophageal squamous cell carcinoma; ESD, endoscopic submucosal dissection; N/A, not applicable.

^*Results included entire study population including T1a and T1b outcomes and did not separately present outcomes for T1b.

^†This value is mean ± standard deviation (range).